Healthcare Industry News: Adaptive Radiation Therapy
News Release - October 9, 2013
RaySearch Laboratories: First RayStation(R) Order in ScandinaviaSTOCKHOLM--(Healthcare Sales & Marketing Network)--RaySearch Laboratories AB (STO:RAYB) has received an order for its RayStation® treatment planning system from Oslo University Hospital in Oslo, Norway.
Oslo University Hospital is a highly specialized public hospital for citizens of the South-Eastern Health Region of Norway including Oslo. The hospital also has a nationwide responsibility for a number of national and multi-regional assignments. It is a Comprehensive Cancer Center including an institute of Cancer Research and a Cancer Registry, and has several national centers of competence. The hospital is Scandinavia’s largest, carrying out more than 1.2 million patient treatments annually, and is responsible for approximately 50 percent of all medical and healthcare research conducted at Norwegian hospitals. RayStation® will be used at the hospital’s unit for radiation therapy at the Norwegian Radium Hospital which is one of the largest radiation therapy centers in Northern Europe.
The hospital will primarily use RayStation® to perform Adaptive Radiation Therapy. This is an advanced form of radiation therapy where the delivered dose is adjusted continuously during the course of treatment to account for changes occurring in the patient’s anatomy. This has a significant potential to increase the tumor control probability and at the same time reduce the risk for side effects by sparing healthy tissue. The clinic will also use RayStation® to perform treatment planning of IMRT treatments and rotational mARC treatments that are carried out with Artiste linear accelerators from Siemens.
“We are really looking forward to start implementing Adaptive Radiation Therapy to further improve the precision in our radiation treatments. This requires very sophisticated software tools and RayStation® really stands out as the best treatment planning solution on the market for adaptive therapy. I see this as a starting point of a deep collaboration with RaySearch for both clinical and research applications”, says Dr. Karsten Eilertsen, Head of Radiotherapy Physics.
“We have previously sold RayStation® to clinics all over the world but being a Scandinavian company it is of course an important milestone for us to get our first RayStation® customer in our home region. Oslo University Hospital is an excellent clinic with extensive research programs in areas where we are highly active so I am fully convinced that this will be a very fruitful partnership”, says Johan Löf, CEO of RaySearch.
RayStation® integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D Adaptive Radiation Therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron and proton therapy. The system is built on the latest software architecture and has a graphical user interface offering state-of-the-art usability.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch’s products are mainly sold through license agreements with leading partners such as Philips, Nucletron, IBA, Varian, Accuray and Brainlab. To date, 15 products have been launched through partners and RaySearch’s software is used at over 2,000 clinics in more than 30 countries. In addition, RaySearch offers the proprietary treatment planning system RayStation® directly to clinics. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm and the company is listed in the Small Cap segment on NASDAQ OMX Stockholm.
For more information about RaySearch, visit www.raysearchlabs.com
Source: RaySearch Laboratories
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.